Clinical Trial Update: An Open-Label Clinical Trial of Replagal Enzyme Therapy in Children Ages 7-17 Years With Fabry Disease [Phase 2]

View source ↗

Summary

An open-label Phase 2 trial evaluating agalsidase alfa (Replagal) enzyme therapy in children ages 7-17 with Fabry disease; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• Replagal (agalsidase alfa)

Snippet

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) | Conditions: Fabry Disease | Phase 2 | Status: COMPLETED